NCT05637606

Brief Summary

This study is a multicenter randomized controlled trial comparing two strategies of mean arterial blood pressure management (MAP ≥ 80mmHg vs MAP ≥ 65 mmHg) in high-risk surgical patients undergoing elective laparotomic/laparoscopic surgery.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
636

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Mar 2023

Typical duration for not_applicable

Geographic Reach
1 country

18 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 24, 2022

Completed
11 days until next milestone

First Posted

Study publicly available on registry

December 5, 2022

Completed
3 months until next milestone

Study Start

First participant enrolled

March 6, 2023

Completed
2.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 21, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 21, 2025

Completed
Last Updated

June 11, 2025

Status Verified

June 1, 2025

Enrollment Period

2.2 years

First QC Date

November 24, 2022

Last Update Submit

June 8, 2025

Conditions

Keywords

Blood pressureIntraoperative HypotensionPostoperative complicationsPostoperative mortality

Outcome Measures

Primary Outcomes (1)

  • Composite endpoint of postoperative mortality and at least one major organ dysfunction (see description in the secondary outcomes).

    Composite postoperative outcome

    up to 30 days after operation

Secondary Outcomes (8)

  • Hospital stay (days)

    up to 30 days after operation

  • ICU stay (days)

    up to 30 days after operation

  • ICU readmission

    up to 30 days after operation

  • Sequential Organ Failure Assessment (SOFA) scores on postoperative

    up to 7 days after operation

  • Overall intraoperative fluid balance

    day 1 after the operation

  • +3 more secondary outcomes

Other Outcomes (5)

  • CARDIOVASCULAR complications

    day 7 after operation

  • NEUROLOGICAL complications

    day 7 after operation

  • RESPIRATORY

    day 7 after operation

  • +2 more other outcomes

Study Arms (2)

MAP 80

EXPERIMENTAL

Intervention group: intraoperative mean blood pressure target \> 80 mmHg. Treatment of hypotension (defined as a mean blood pressure of below 80 mmHg) using intravenous bolus or continuous infusion of vasopressors, or fluids using a dedicated algorithm considering the pulse pressure or stroke volume variation and the mini fluid challenge to optimize mean blood pressure values.

Drug: EphedrineDrug: NorepinephrineDrug: Etilefrine Hydrochloride bolusDiagnostic Test: Use of pulse pressure and stroke volume variation (PPV and SVV); use of Mini Fluid Challenge (mini_FC)

MAP 65

OTHER

Control group: intraoperative mean blood pressure target \> 65 mmHg. Treatment of hypotension (defined as a mean blood pressure of below 65 mmHg) using intravenous bolus or continuous infusion of vasopressors, or fluids using a dedicated algorithm considering the pulse pressure or stroke volume variation and the mini fluid challenge to optimize mean blood pressure values.

Drug: EphedrineDrug: NorepinephrineDrug: Etilefrine Hydrochloride bolusDiagnostic Test: Use of pulse pressure and stroke volume variation (PPV and SVV); use of Mini Fluid Challenge (mini_FC)

Interventions

In both the group, the target MAP can be maintained by means of bolus of ephedrine (2.5 mg). The maximal dose for the ephedrine allowed is 25 mg (10 boluses of 2.5 mg), after this threshold a continuous infusion of norepinephrine will be started

Also known as: Ephedrine bolus
MAP 65MAP 80

In both the group, the target MAP can be maintained by means of bolus of ephedrine (2.5 mg) or Etilefrine (1 mg). The continuous infusion of norepinephrine, as decided by the attending anesthetist, may be started at any point of the intraoperative period. The starting dose of norepinephrine is the lowest needed to reach the predefined MAP target.

Also known as: norepinephrine infusion
MAP 65MAP 80

The maximal dose for the etilefrine allowed is 10 mg (10 boluses of 1 mg), after this threshold a continuous infusion of norepinephrine will be started

MAP 65MAP 80

PPV, SVV and mini\_FC will guide fluid bolus administration during an episode of intraoperative hypotension, following two predefined algorithms for laparotomic/non laparotomic surgery

Also known as: Hemodynamic optimization
MAP 65MAP 80

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Adult patients ≥ 60 years
  • History of chronic hypertension requiring home therapy.
  • Scheduled for major elective abdominal surgery (laparoscopic, robotic or laparotomic)
  • Expected surgical duration of at least 3 hours.
  • Needing invasive arterial and hemodynamic monitoring as decided by the attending anesthetist, according to the rules of good clinical practice of each involved center.
  • AND
  • At increased risk of postoperative complications (at least one of the following):
  • American Society of Anesthesiologists (ASA) class 3 or 4
  • Known or documented history of coronary artery disease (angina, myocardial infarction or acute coronary syndrome).
  • Known or documented history of peripheral vascular disease.
  • Known or documented history of heart failure requiring treatment.
  • Ejection fraction less than 30% (echocardiography)
  • Signs of diastolic moderate to severe dysfunction or chronic hypertensive cardiomyopathy (echocardiography)
  • Moderate or severe valvular heart disease (echocardiography)
  • Diagnosis of Chronic Obstructive Pulmonary Disease (COPD) Radiographically confirmed or according to Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria.
  • +5 more criteria

You may not qualify if:

  • Refusal of consent
  • Chronic kidney disease with glomerular filtration rate \<30 ml/min/1.73 m2 or requiring renal-replacement therapy for end-stage renal disease
  • Acute cardiovascular event, including acute or decompensated heart failure and acute coronary syndrome (within prior 30 days).
  • Urgent or time-critical surgery
  • Aortic or Renal vascular surgery (including nephrectomy)
  • Liver Surgery
  • Neurosurgery
  • Surgery for palliative treatment only or ASA physical status 5
  • Pregnancy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (18)

Ospedali Riuniti Foggia- Università di Foggia

Foggia, Apulia, Italy

Location

Department of Anesthesia and Intensive Care, University Hospital of Modena

Modena, Emilia-Romagna, Italy

Location

Policlinico A. Gemelli

Rome, Lazio, Italy

Location

Humanitas Research Hospital

Rozzano, MILANO, 20089, Italy

Location

Fondazione Istituto San Raffaele G. Giglio

Cefalù, Sicily, Italy

Location

Careggi University Hospital

Florence, Tuscany, 50134, Italy

Location

Unit of Anesthesiology and Intensive Care B, Department of Surgery, Dentistry, Gynecology and Pediatrics, AOUI-University Hospital Integrated Trust of Verona

Verona, Veneto, Italy

Location

Azienda Ospedaliero - Universitaria SS. Antonio e Biagio e Cesare Arrigo

Alessandria, Italy

Location

ASST Grande Ospedale Metropolitano Niguarda

Milan, Italy

Location

Istituto Nazionale dei Tumori

Milan, Italy

Location

Ospedale Antonio Cardarelli

Napoli, Italy

Location

Azienda sanitaria Friuli Occidentale (AsFO]

Pordenone, Italy

Location

Ospedale Santo Stefano

Prato, Italy

Location

Ospedale S. Anna di Castelnovo ne' Monti

Reggio Emilia, Italy

Location

Sant'Eugenio ASL Roma 2:

Roma, Italy

Location

Azienda Ospedaliero Universitaria di Sassari

Sassari, Italy

Location

Ospedale Molinette

Torino, Italy

Location

Ospedale Santa Chiara di Trento

Trento, Italy

Location

Related Publications (2)

  • Messina A, Robba C, Calabro L, Zambelli D, Iannuzzi F, Molinari E, Scarano S, Battaglini D, Baggiani M, De Mattei G, Saderi L, Sotgiu G, Pelosi P, Cecconi M. Association between perioperative fluid administration and postoperative outcomes: a 20-year systematic review and a meta-analysis of randomized goal-directed trials in major visceral/noncardiac surgery. Crit Care. 2021 Feb 1;25(1):43. doi: 10.1186/s13054-021-03464-1.

    PMID: 33522953BACKGROUND
  • Walsh M, Devereaux PJ, Garg AX, Kurz A, Turan A, Rodseth RN, Cywinski J, Thabane L, Sessler DI. Relationship between intraoperative mean arterial pressure and clinical outcomes after noncardiac surgery: toward an empirical definition of hypotension. Anesthesiology. 2013 Sep;119(3):507-15. doi: 10.1097/ALN.0b013e3182a10e26.

    PMID: 23835589BACKGROUND

MeSH Terms

Conditions

Postoperative Complications

Interventions

EphedrineNorepinephrine

Condition Hierarchy (Ancestors)

Pathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

PropanolaminesAmino AlcoholsAlcoholsOrganic ChemicalsPropanolsAminesPhenethylaminesEthylaminesEthanolaminesBiogenic MonoaminesBiogenic AminesCatecholaminesCatecholsPhenolsBenzene DerivativesHydrocarbons, AromaticHydrocarbons, CyclicHydrocarbons

Study Officials

  • Antonio Messina

    Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milano, Italy

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Masking Details
The trial intervention is not blinded for investigators, clinical staff, and patients, as blinding intraoperative MAP target is not feasible. The physicians of each center assessing all postoperative outcomes will be masked for the allocation.
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: The study will be a multicentric, randomized, non-blinded clinical trial. Eligible patients will be assigned in a 1:1 ratio to either a to control or treatment group. Randomization list will be created by a computer with the use of a permuted block design and embedded in the Electronic Case Report Form. Randomization will be performed using a 'block of 6" and stratified according to predefined baseline characteristics: 1. Age ≥ 75 years 2. Preoperative systolic pressure 1. \< 140 mmHg 2. ≥ 140 mmHg
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

November 24, 2022

First Posted

December 5, 2022

Study Start

March 6, 2023

Primary Completion

May 21, 2025

Study Completion

May 21, 2025

Last Updated

June 11, 2025

Record last verified: 2025-06

Locations